Skip to main content
SpringerLink
Log in

Is there increasing evidence that the risks of rhAPC may outweigh its benefits?

  • Correspondence
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Eichacker PQ, Natanson C (2007) Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med 33:396–399

    Article  PubMed  Google Scholar 

  2. Kanji S, Perreault MM, Chant C, Williamson D, Burry L (2007) Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Med 33:517–523

    Article  PubMed  Google Scholar 

  3. Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D (2007) Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med 33:426–434

    Article  PubMed  Google Scholar 

  4. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Wesley Ely E, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709

    Article  PubMed  CAS  Google Scholar 

  5. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33:2266–2277

    Article  PubMed  CAS  Google Scholar 

  6. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B (2007) Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomized controlled trial. Lancet 369:836–843

    Article  PubMed  CAS  Google Scholar 

  7. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353:1332–1341

    Article  PubMed  CAS  Google Scholar 

  8. Tanzi M (2004) Use of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis: medical use evaluation by Novation, the supply company of VHA and UHC. Novation

Download references

Author information

Authors and Affiliations

  1. Department of Intensive Care Medicine, University Hospital of Heraklion, Medical School, University of Crete, Heraklion, Crete, Greece

    Maria Plataki, Katerina Vaporidi & Dimitris Georgopoulos

Authors
  1. Maria Plataki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katerina Vaporidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dimitris Georgopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dimitris Georgopoulos.

Additional information

This comment refers to the editorial available at: http://dx.doi.org/10.1007/s00134-007-0556-8.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Plataki, M., Vaporidi, K. & Georgopoulos, D. Is there increasing evidence that the risks of rhAPC may outweigh its benefits?. Intensive Care Med 33, 1485–1486 (2007). https://doi.org/10.1007/s00134-007-0707-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-007-0707-y

Keywords

Search

Navigation